Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
547.72
+0.43 (+0.08%)
Streaming Delayed Price
Updated: 3:28 PM EDT, Aug 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
76
77
Next >
Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance
↗
May 05, 2025
Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.
Via
Benzinga
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Sales Below Analyst Estimates In Q1 Earnings
May 05, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of...
Via
StockStory
Vertex Reports First Quarter 2025 Financial Results
May 05, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum?
↗
May 05, 2025
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, charts show bullish trend.
Via
Benzinga
Earnings Scheduled For May 5, 2025
↗
May 05, 2025
Via
Benzinga
Earnings Outlook For Vertex Pharmaceuticals
↗
May 02, 2025
Via
Benzinga
Stocks Pause Gains As Treasury Yields Rise: What's Driving Markets Monday?
↗
May 05, 2025
Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services...
Via
Benzinga
Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
May 05, 2025
Via
Benzinga
Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now
↗
May 05, 2025
Now may be a smart time to buy small stakes in these fundamentally robust companies.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
3 No-Brainer Stocks to Buy in May
↗
May 05, 2025
Via
The Motley Fool
5 Growth Stocks to Buy in May and Go Away
↗
May 04, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Government
World Trade
Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow
May 04, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
S&P Global, Berkshire Hathaway, CME Group And A Health Care Stock: CNBC's 'Final Trades'
↗
May 01, 2025
Via
Benzinga
Topics
Stocks
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential
↗
April 30, 2025
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential
Via
Chartmill
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
↗
April 30, 2025
Via
The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
April 29, 2025
Via
Benzinga
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
↗
April 28, 2025
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...
Via
Talk Markets
Topics
ETFs
Stocks / Equities
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
↗
April 28, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Energy
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
↗
April 22, 2025
Via
The Motley Fool
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
↗
April 22, 2025
Via
The Motley Fool
Topics
Government
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts
↗
April 22, 2025
Via
Benzinga
Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right
↗
April 22, 2025
Via
The Motley Fool
Topics
Economy
Government
World Trade
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
↗
April 21, 2025
Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and potential upside surprises.
Via
Benzinga
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next
↗
April 18, 2025
Via
The Motley Fool
Topics
Government
World Trade
Peering Into Vertex Pharmaceuticals's Recent Short Interest
↗
April 17, 2025
Via
Benzinga
As The Nasdaq 100 Index Crashes, Is It Safe To Buy The Dip?
↗
April 17, 2025
The Nasdaq 100 Index remains under pressure after forming a death cross pattern a few weeks ago. It has retreated to $18,257, down by over 17.8% from its highest point this year.
Via
Talk Markets
Topics
Stocks / Equities
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
↗
April 16, 2025
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...
Via
Benzinga
Topics
Government
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce
↗
April 15, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Government
Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades
↗
April 12, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Government
Stocks
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'
↗
April 11, 2025
CrowdStrike has expanded its partnership with Google Cloud to enable end-to-end security for AI innovation.
Via
Benzinga
Topics
Artificial Intelligence
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
76
77
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.